noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

Politics and Policy

AICPA - American Institute of[...]

CIMA: Autumn Budget must move businesses from survival to growth
The United States Army

USAREUR-AF, NATO Allies conclude Exercise Avenger Triad 26
New York State Commission on[...]

Censure of NYC Criminal Court Judge Jeffrey A. Gershuny (New York County)

Pharmaceuticals and Biotechnology

Netris Pharma SAS

10/19/2025 | Press release | Archived content

NETRIS Pharma to present the IMMUNONET abstract at the 2025 ESMO in Berlin

IMMUNONET : A Proof-of-Concept Phase II evaluating NP137 as add-on therapy in solid tumors treated with standard immunotherapies: interim analysis of primary and secondary refractory cohorts FPN 966.

The NETRIS Pharma's team presents the below abstract at the ESMO in Berlin in October 2025 :

right click on the image to open it in a new tab, or to save it

Netris Pharma SAS published this content on October 19, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 15, 2026 at 09:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format